TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02209103

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lozenge containing citrus flavonoid

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lozenge containing citrus flavonoid formulation

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Identical looking placebo
Study: NCT00118612

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tree MATA MPL - Therapeutic Regimen
Description: 600, 1600, 4000, 4000 SU/0.5 mL

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tree MATA MPL - Intermediate dose
Description: 300, 600, 1600, 1600 SU/0.5 mL

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tree MATA MPL - Low dose
Description: 300, 300, 300, 300 SU/0.5 mL

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: L-tyrosine 2% w/v , 4 injections
Study: NCT01721954

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFOX6m

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX6m

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SIR-Spheres microspheres
Study: NCT02840864

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sonography assisted breast surgery

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sonography assisted breast surgery
Study: NCT00867971

Intervention type: OTHER
Intervention: Measuring intraoccular pressure
Description: Measurement of intraoccular pressure by tonometry

Intervention type: OTHER
Intervention: Measuring intraoccular pressure
Description: Measurement of intraoccular pressure by tonometry
Study: NCT03353597

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Plasma Transfusion
Description: All subjects will receive monthly, 2-unit transfusions of young healthy male donor plasma for total of 6 treatments. The plasma will be administered at a transfusion services facility in a manner consistent with generally accepted and standard guidelines for plasma transfusions.
Study: NCT01508390

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: CyberKnife Boost
Description: 21 Gy in 7 Gy per day, 3 fractions, Every other day
Study: NCT03321409

Intervention type: DIAGNOSTIC_TEST
Intervention: The general population
Description: After recruiting participants, collecting the baseline data, the SSS-CN and PHQ-15 will be carried out. Then validating the reliability, validity of the SSS-CN will be compared with the PHQ-15.

Intervention type: DIAGNOSTIC_TEST
Intervention: Patients with suspected CAD
Description: In patients with suspected CAD, after recruiting participants, collecting the baseline data, the SSS-CN and PHQ-15 will be carried out before undergo coronary angiography. Then the prevalence of somatic symptoms will be investigated.
Study: NCT03671785

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRIM-DJ2727
Description: Twice filtered fecal microbiota product from three screened healthy donors will be lyophilized and encapsulated in enteric-coated capsules. Each dose of enteric coated capsules consists of 60 grams of stool and will be administered orally twice-weekly for 12 consecutive weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo oral capsule
Description: Placebo capsule will be identical to PRIM-DJ2727 but will not contain intestinal bacteria. The placebo will consist of Lactose (spray-dried United States Pharmacopeia (USP) 64.385gm), food color, powdered Black, Brown, and Yellow in the enteric capsules. Placebo will be administered orally twice-weekly for 12 consecutive weeks
Study: NCT06297044

Intervention type: OTHER
Intervention: Neuropsychological assessment
Description: * APACS assessing various aspects of pragmatic communication abilities;~* SET assessing cognitive and emotional theory of mind;~* COAST assessing functional communication impairments in daily activities and their impact on the quality of life after the illness onset;~* PWB assessing the individual's perceived quality of life and psychological well-being;~* other neuropsychological assessment tools depending on the participant's pathology and routinely used in the clinical practice within the Institution.
Study: NCT02286453

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benjakul recipe
Description: Benjakul recipe capsule at dose of 100 mg three times a day after meal daily for 28 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: diclofenac
Description: diclofenac capsule at dose of 25 mg three times a day after meal daily for 28 days
Study: NCT02693951

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefotiam
Description: Prophylactic use of antibiotics group: Half an hour before endoscopic treatment, cefotiam 2.0g intravenous
Study: NCT01658111

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robot Group
Description: The MIT-MANUS/InMotion2 (Interactive Motion Technologies, Inc., Watertown, MA, USA) system has two translational degrees of freedom (dof): shoulder abduction-adduction (ab-ad), elbow flexion-extension (flexext).~The robotic system supports the execution of reaching movements in the horizontal plane through an assist as needed control strategy. The robot can guide the movement of the upper limb of the patients and record end-effector physical quantities such as the position, velocity, and applied forces. The device is designed to have a low intrinsic end-point impedance (i.e., be back-drivable to easily carry the weight of the patient's arm, to execute movements without constraint and offer minimal resistance. A 3-dof force transducer is placed at the robots end-effector, as well.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional physiotherapy
Description: Active or passive exercises.
Study: NCT00672451

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: rhubarb extract
Description: titrate rhubarb extract titrated up to 6grams daily by mouth

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo titrated up to 6 pills daily as patient tolerates
Study: NCT00661843

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Integrated Yoga style practice
Description: Intervention constitutes of 2 supervised yoga style classes per week incorporating gentle postures,relaxation and meditation sequences. In addition daily home based sessions of yogic relaxation, and meditation a an audio CD
Study: NCT02292472

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type A
Description: Inject intramuscularly once in visit 2

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Inject intramuscularly once in visit 2
Study: NCT02812056

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alisertib
Description: Dose Escalation Phase:~Starting dose of Alisertib: 30 mg by mouth 2 times a day on Days 1 - 7 each 21 day cycle.~Dose Expansion Phase: Maximum tolerated dose from Dose Escalation Phase.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-228
Description: Dose Escalation Phase:~Starting dose of TAK-228: 1 mg by mouth daily Days 3 - 18, with the exception of 2 mg daily Days 3 - 7 and 10 - 14 schedule in a 21 day cycle.~Dose Expansion Phase: Maximum tolerated dose from Dose Escalation Phase.
Study: NCT02931370

Intervention type: DIETARY_SUPPLEMENT
Intervention: Dietary Supplement: Intensive dietary intervention
Description: Participants receive a hypo-caloric formula diet containing 800 to 1,000 kcal/day. The formula diet consists of ready-to-use meal bars and powders to mix with water to make shakes, soups, or porridge. The weight loss programme consists of an 8-week period with full meal replacement by a standard liquid energy intake protocol. To facilitate compliance with the programme, participants will be scheduled for weekly facility-based group sessions with 6-8 participants led by a dietician. The recommendations for daily nutrient intake will be met.
Study: NCT03394131

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hylase
Description: hydro-dissection injection of median nerve inside carpal tunnel using hyalase and 10 cc saline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: hydro-dissection injection of median nerve inside carpal tunnel using 10 IU insulin and 10 cc saline

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: hydro-dissection injection of median nerve inside carpal tunnel using 10 cc saline
Study: NCT01004523

Intervention type: GENETIC
Intervention: fluorescence in situ hybridization

Intervention type: GENETIC
Intervention: loss of heterozygosity analysis

Intervention type: GENETIC
Intervention: polymerase chain reaction

Intervention type: OTHER
Intervention: flow cytometry

Intervention type: OTHER
Intervention: immunohistochemistry staining method
Study: NCT01896726

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Microgynon
Description: Administered orally
Study: NCT04311645

Intervention type: DRUG
Group type: OTHER
Intervention: Activated charcoal
Description: Activated charcoal

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Dry seeds
Description: Dry seeds
Study: NCT00705601

Intervention type: PROCEDURE
Intervention: PSG
Description: PSG (polysomnography) for adaptation night, day 2 evening, and day 3 evening--used to identify suitable Nonrestorative Sleep candidates to participate in focus groups.
Study: NCT00487032

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxymetazoline 0.05% w/v
Description: 2 squirts in each nostril thrice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 50 micrograms per actuation
Description: 2 Squirts in each nostril twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prazosin hydrochloride
Description: Prazosin 1mg one dose only

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to Prazosin
Description: Placebo 1 tablet one dose only
Study: NCT02134509

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental App
Description: It is comprised of twenty-two modules of 10-15 minutes each, designed to teach behavioral strategies for smoking cessation using psychoeducation-based audio and videos, animations to reinforce key concepts, and in vivo exercises. In addition, 5 bonus modules become available upon completion of earlier modules; these may be accessed for additional practices to bolster other modules

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator App
Description: It is comprised of 6 prompts per day asking individuals about their experience, behavior, and smoking habits, for 22-days.
Study: NCT01342432

Intervention type: OTHER
Group type: OTHER
Intervention: General exercise only
Description: exercises for stretch and strength of paraspinal and abdominal muscles

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balance reeducation plus general exercise
Description: patients perform balance reeducation exercises in addition to general exercises for stretch and strength of back and abdominal muscles
Study: NCT01656213

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Computer-based target pursuit task (created using E-Prime software) and visual-feedback handgrip force transducer (CurrentDesigns 2012).
Description: Subjects will be encouraged to perform the exercise 2-3 times per dialysis session depending upon mood, although will be permitted to skip sessions if they do not feel well or motivated. The laptop program time-stamps each session, and records a time-series of duration, force and accuracy of hand grip.
Study: NCT01594645

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sperm selection by conventional / polarized light microscopy
Description: Selecting spermatozoa for ICSI using conventional and polarized light microscopy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sperm selection by conventional / polarized light microscopy
Description: Selecting spermatozoa for ICSI using conventional and polarized light microscopy
Study: NCT04119843

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mangoral
Description: 800 mg manganese chloride \[II\] tetrahydrate, 500 mg L-alanine, and 800 IU vitamin D3
Study: NCT00856245

Intervention type: DRUG
Group type: OTHER
Intervention: Rituximab
Description: 375 MG/M2 (milligram per meter squared) given IV (intravenously) weekly x 4-8 doses.
Study: NCT01512550

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: GF hip guide
Description: Using GF hip guide to measure and control the peroperative positioning of the hip stem

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stryker Navigation System
Description: Using Orthomap Modular Hip Software to navigate the operation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ABG II modular femoral component
Description: A hip prosthesis made by Stryker. It has the same basic shape as the ABG II femoral component but has a modular neck system allowing it to better follow the patient specific hip anatomy regarding offset, varus-valgus angle and rotation in the anteroposterior plane.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ABG II modular femoral component
Description: A hip prosthesis made by Stryker. It has the same basic shape as the ABG II femoral component but has a modular neck system allowing it to better follow the patient specific hip anatomy regarding offset, varus-valgus angle and rotation in the anteroposterior plane.
Study: NCT01241331

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLI1100
Description: BLI110 topical cream

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle cream
Description: Vehicle topical cream
Study: NCT03440970

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lysine Chloride
Description: Patients will receive the study drug twice a day for 5 days.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will receive the placebo twice a day for 5 days.
Study: NCT01814072

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Buddy Training
Description: Participants will have a buddy that will be trained via webinars to be a supportive buddy

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Buddy Training
Description: Participants will have a buddy that will be trained via webinars to be a supportive buddy

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Buddy Training
Description: Participants will have a buddy that will be trained via webinars to be a supportive buddy

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Buddy Training
Description: Participants will have a buddy that will be trained via webinars to be a supportive buddy

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Buddy Training
Description: Participants will have a buddy that will be trained via webinars to be a supportive buddy

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Buddy Training
Description: Participants will have a buddy that will be trained via webinars to be a supportive buddy

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Buddy Training
Description: Participants will have a buddy that will be trained via webinars to be a supportive buddy

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Buddy Training
Description: Participants will have a buddy that will be trained via webinars to be a supportive buddy
Study: NCT00760747

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atomoxetine
Description: 1.2 mg/kg/day up to 1.8 mg/kg/day, orally (PO)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atomoxetine
Description: 1.2 mg/kg/day up to 1.8 mg/kg/day, orally (PO)
Study: NCT01816347

Intervention type: PROCEDURE
Intervention: Routine PCI
Study: NCT00592189

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: blood draw
Description: blood collection
Study: NCT01021371

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Two step intervention including patient interview followed by an extended information routine to the patients' GP about the patients' rehabilitation needs
Description: The intervention consists of an extended information routine from hospital to GP based on individual interviews with the patients in the intervention group and a specific encouragement of the patients' GP to play a proactive role in the patients' rehabilitation course. The individual needs concerning the different types of consequences of the disease and following rehabilitation needs will be brought into focus. The control group is assigned to usual procedures.
Study: NCT04115189

Intervention type: DRUG
Intervention: Sunitinib
Description: Patients to receive Sunitinib as first line therapy for mRCC
Study: NCT02529423

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Multi-nutrient supplement
Description: * Omega 3 fatty acids~* Folic acid~* Calcium~* Selenium~* Vitamin D3

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Multi-nutrient supplement
Description: * Omega 3 fatty acids~* Folic acid~* Calcium~* Selenium~* Vitamin D3

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Activation
Description: 21 sessions (15 individual sessions and 6 group sessions) The intervention will include detailed analysis of each individual's behavior to determine idiosyncratic triggers and functions of unhelpful (e.g., mood-related snacking) and helpful food-related behavior, thereby, to reinforce helpful behaviors and to implement effective alternatives to unhelpful behaviors, building on behavioural approaches proven effective in depression.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Activation
Description: 21 sessions (15 individual sessions and 6 group sessions) The intervention will include detailed analysis of each individual's behavior to determine idiosyncratic triggers and functions of unhelpful (e.g., mood-related snacking) and helpful food-related behavior, thereby, to reinforce helpful behaviors and to implement effective alternatives to unhelpful behaviors, building on behavioural approaches proven effective in depression.
Study: NCT02110628

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Roux-en-Y anastomosis
Description: Roux-en-Y anastomosis

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Roux-en-Y+Pouch anastomosis
Description: Roux-en-Y+Pouch anastomosis
Study: NCT04052516

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icosabutate
Description: Icosabutate oral capsule once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icosabutate
Description: Icosabutate oral capsule once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo oral capsule
Study: NCT00864305

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin 400 mg capsules
Description: A: Experimental Subjects received Purepac formulated products under fed conditions

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NEURONTIN® 400 mg capsules
Description: B: Active comparator Subjects received Parke-Davis's marketed product

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin 400 mg capsules, single dose
Description: C: Experimental Subjects received Purepac formulated products under fasting conditions
Study: NCT03574688

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Water
Description: Increased daily water intake with 1.5 Liters of water per day on top of habitual water intake.
Study: NCT02529423

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo pills identical in look and taste but including no active ingredients

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo pills identical in look and taste but including no active ingredients
Study: NCT02365038

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Driving pressure limited ventilation
Description: We will use volume controlled ventilation or pressure support in the weaning phase. We will adjust tidal volume between 3 and 8 mL/Kg of predicted body weight in order to achieve a driving pressure of 13 cmH2O. The respiratory rate will be titrated to achieve a pH between 7.30 and 7.45 (maximum respiratory rate is 50 breathings per minute). We will not limit plateau pressure in this arm.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional ventilation
Description: ARDSNet Strategy: conventional mechanical ventilation strategy with tidal volume between 4 and 6 mL/kg of predicted body weight and plateau pressure limited to 30 cmH2O.
Study: NCT03323697

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SZ-05
Description: 2.5g a day (3 capsules twice a day)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram Pill
Description: 10 mg capsule plus 5 placebo capsules
Study: NCT00222014

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TIPS
Description: Transjugular intrahepatic portosystemic shunt with covered PTFE

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Paracenthese
Description: Paracenthese
Study: NCT04515277

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 40 g Gum acacia (FibregumTM)
Description: Applied in 300 mL of orange juice with breakfast (single use at visit)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 20 g Gum acacia (FibregumTM)
Description: Applied in 300 mL of orange juice with breakfast (single use at visit)

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: 0 g Gum acacia (FibregumTM)
Description: 300 mL of orange juice with breakfast (single use at visit)
Study: NCT02875717

Intervention type: DRUG
Intervention: Acetylsalicylic acid

Intervention type: DRUG
Intervention: low molecular weight heparin